亚虹医药(688176)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

688176 亚虹医药

已收盘 12-13 15:00:01

{"stockData":{"symbol":"688176","market":"SH","secType":"STK","nameCN":"亚虹医药","latestPrice":7.6,"timestamp":1734073201000,"preClose":7.85,"halted":0,"volume":6320839,"delay":0,"floatShares":371000000,"shares":570000000,"eps":-0.7075,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.25,"latestTime":"12-13 15:00:01","open":7.82,"high":7.84,"low":7.6,"amount":48607700,"amplitude":0.0306,"askPrice":7.61,"askSize":57,"bidPrice":7.6,"bidSize":194,"shortable":0,"etf":0,"ttmEps":-0.7075,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1734312600000},"adr":0,"adjPreClose":7.85,"symbolType":"stock_kcb","openAndCloseTimeList":[[1734053400000,1734060600000],[1734066000000,1734073200000]],"highLimit":8.64,"lowLimit":7.06,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":570000000,"pbRate":2.08,"roa":"--","roe":"--","epsLYR":-0.7,"committee":0.218023,"marketValue":4332000000,"floatMarketCap":2823000000,"peRate":-10.74205,"changeRate":-0.0318,"turnoverRate":0.017,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2024-12-16。","afterMarket":{"amount":0,"volume":0,"close":7.6,"buyVolume":0,"sellVolume":0,"time":1734075239464,"indexStatus":"已收盘 12-13 15:30:00","preClose":7.85}},"requestUrl":"/m/hq/s/688176/","defaultTab":"news","newsList":[{"id":"2486309448","title":"亚虹医药-U大涨 近半年券商看好","url":"https://stock-news.laohu8.com/highlight/detail?id=2486309448","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486309448?lang=zh_cn&edition=full","pubTime":"2024-11-26 09:49","pubTimestamp":1732585763,"startTime":"0","endTime":"0","summary":"11月26日，亚虹医药-U股价大幅上涨，截至09点49分，亚虹医药-U上涨5.11%，报7.81元/股，成交1553万元，换手率0.55%，振幅5.52%。资金动向截止发稿，亚虹医药-U获得主力净流入224万元，其中超大单流入77万元，大单流入146万元。主营业务及业绩亚虹医药-U公司主营业务为创新药物的研发、生产和销售。最新财报显示，今年三季报，亚虹医药-U实现营业收入1.39亿元，同比增长4537.79%，净利润为-2.71亿元，同比减少1.04%，基本每股收益为-0.48元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241126094938a255c486&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241126094938a255c486&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2485816322","title":"亚虹医药-U跌5% 2券商增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2485816322","media":"智选洞察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485816322?lang=zh_cn&edition=full","pubTime":"2024-11-22 14:45","pubTimestamp":1732257913,"startTime":"0","endTime":"0","summary":"11月22日，亚虹医药-U股价大幅下跌，截至14点45分，亚虹医药-U下跌5.04%，报7.35元/股，成交4487万元，换手率1.60%。资金动向截止发稿，亚虹医药-U获得主力净流出709万元，其中超大单流出313万元，大单流出394万元。主营业务及业绩亚虹医药-U公司主营业务为创新药物的研发、生产和销售。最新财报显示，今年三季报，亚虹医药-U实现营业收入1.39亿元，同比增长4537.79%，净利润为-2.71亿元，同比减少1.04%，基本每股收益为-0.48元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122145843a24d3594&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122145843a24d3594&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688176"],"gpt_icon":0},{"id":"2484338491","title":"亚虹医药-U涨5.24% 生物医药论坛召开","url":"https://stock-news.laohu8.com/highlight/detail?id=2484338491","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484338491?lang=zh_cn&edition=full","pubTime":"2024-11-20 10:16","pubTimestamp":1732068993,"startTime":"0","endTime":"0","summary":"11月20日，亚虹医药-U股价大幅上涨，截至10点16分，亚虹医药-U上涨5.24%，报7.83元/股，成交2893万元，换手率1.02%。资金动向截止发稿，亚虹医药-U获得主力净流入425万元，其中超大单流入131万元，大单流入293万元。主营业务及业绩亚虹医药-U公司主营业务为创新药物的研发、生产和销售。最新财报显示，今年三季报，亚虹医药-U实现营业收入1.39亿元，同比增长4537.79%，净利润为-2.71亿元，同比减少1.04%，基本每股收益为-0.48元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120101649abd0b50f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120101649abd0b50f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["161726","688176","399441","BK0239"],"gpt_icon":0},{"id":"2484921869","title":"亚虹医药：11月19日召开业绩说明会，投资者参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2484921869","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484921869?lang=zh_cn&edition=full","pubTime":"2024-11-19 17:03","pubTimestamp":1732007029,"startTime":"0","endTime":"0","summary":"证券之星消息，2024年11月19日亚虹医药发布公告称公司于2024年11月19日召开业绩说明会。亚虹医药2024年三季报显示，公司主营收入1.39亿元，同比上升4537.79%；归母净利润-2.71亿元，同比下降1.04%；扣非净利润-2.86亿元，同比上升2.65%；其中2024年第三季度，公司单季度主营收入5845.82万元，同比上升1903.16%；单季度归母净利润-8685.02万元，同比下降5.13%；单季度扣非净利润-8907.22万元，同比下降2.36%；负债率10.12%，投资收益1019.75万元，财务费用-1563.99万元，毛利率79.44%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111900027287.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2484951719","title":"亚虹医药前3季亏此前6年均亏 2022年上市即巅峰募25亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2484951719","media":"中国经济网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484951719?lang=zh_cn&edition=full","pubTime":"2024-11-19 10:56","pubTimestamp":1731984960,"startTime":"0","endTime":"0","summary":"中国经济网北京11月19日讯亚虹医药日前披露2024年第三季度报告。　　亚虹医药于2022年1月7日在上交所科创板上市，发行数量为1.1亿股，发行价格为22.98元/股，保荐机构为中信证券（维权）股份有限公司，保荐代表人为杨沁、程杰。　　亚虹医药上市首日开盘即破发，当日盘中最高价报20.00元，此后股价震荡走低。　　　亚虹医药首次公开发行股票的费用总额为1.47亿元，其中中信证券获得承销费及保荐费1.30亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2024-11-19/doc-incwqerw3080481.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-11-19/doc-incwqerw3080481.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2484984576","title":"亚虹医药任命张云女士担任首席医学官","url":"https://stock-news.laohu8.com/highlight/detail?id=2484984576","media":"亚虹医药","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484984576?lang=zh_cn&edition=full","pubTime":"2024-11-18 09:00","pubTimestamp":1731891616,"startTime":"0","endTime":"0","summary":"中国上海，11月18日—聚焦泌尿生殖系统肿瘤及女性健康的全球化创新药公司亚虹医药今天宣布，公司任命张云女士担任首席医学官，向亚虹医药创始人、董事长兼CEO潘柯博士汇报。张云女士首席医学官张云女士在医药行业拥有超过25年的经验，曾在恒瑞医药、赛诺菲巴斯德、武田制药等国内外知名药企担任过临床研究、医学事务和注册事务的高级管理职位。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118111045abcaee3c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118111045abcaee3c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688176"],"gpt_icon":0},{"id":"2482072081","title":"亚虹医药(688176.SH)：APL-1702国际多中心Ⅲ期临床试验已达到主要疗效终点 安全性良好","url":"https://stock-news.laohu8.com/highlight/detail?id=2482072081","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482072081?lang=zh_cn&edition=full","pubTime":"2024-11-12 17:05","pubTimestamp":1731402328,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚虹医药 发布公告，近日，公司产品APL1702用于治疗宫颈高级别鳞状上皮内病变的前瞻、随机、双盲、安慰剂对照的国际多中心Ⅲ期临床试验结果入选2024年国际乳头瘤病毒大会，并以壁报形式发布研究关于不同HPV型别、不同随访时间的HPV清除率分析数据。已完成的统计分析结果显示，该研究已达到主要疗效终点，安全性良好。此外，该研究发现APL-1702组在第6个月时总体HPV清除率、HPV16/18清除率均明显优于安慰剂组。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1209813.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1576","BK0239","03347","688176","BK1141","BK1583"],"gpt_icon":0},{"id":"2482559773","title":"亚虹医药：APL-1702临床试验结果入选2024年IPVC","url":"https://stock-news.laohu8.com/highlight/detail?id=2482559773","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482559773?lang=zh_cn&edition=full","pubTime":"2024-11-12 17:04","pubTimestamp":1731402290,"startTime":"0","endTime":"0","summary":"亚虹医药(688176)11月12日晚间公告，近日，公司产品APL-1702用于治疗宫颈高级别鳞状上皮内病变的前瞻、随机、双盲、安慰剂对照的国际多中心Ⅲ期临床试验结果入选2024年国际乳头瘤病毒大会（IPVC），并以壁报形式发布本研究关于不同HPV型别、不同随访时间的HPV清除率分析数据。目前上述产品的上市申请已获国家药监局受理，尚需经过审评、药品临床试验现场检查、药品生产现场检查和审批等环节，上述产品能否成功上市及上市时间具有不确定性。文章来源：每日经济新闻原标题：亚虹医药：APL-1702临床试验结果入选2024年IPVC","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112172004a22ffa2b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112172004a22ffa2b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2482720509","title":"亚虹医药：APL-1702国际多中心Ⅲ期临床试验结果入选2024年国际乳头瘤病毒大会","url":"https://stock-news.laohu8.com/highlight/detail?id=2482720509","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482720509?lang=zh_cn&edition=full","pubTime":"2024-11-12 17:00","pubTimestamp":1731402051,"startTime":"0","endTime":"0","summary":"亚虹医药公告，公司产品APL-1702用于治疗宫颈高级别鳞状上皮内病变（HSIL）的前瞻、随机、双盲、安慰剂对照的国际多中心Ⅲ期临床试验结果入选2024年国际乳头瘤病毒大会，并以壁报形式发布。该研究已达到主要疗效终点，安全性良好。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111200028394.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["03347","BK1141","BK1583","BK1576","688176","BK0239"],"gpt_icon":0},{"id":"2482722250","title":"亚虹医药：APL-1702临床试验数据入选2024年国际乳头瘤病毒大会","url":"https://stock-news.laohu8.com/highlight/detail?id=2482722250","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482722250?lang=zh_cn&edition=full","pubTime":"2024-11-12 16:44","pubTimestamp":1731401045,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1583","03347","688176","BK0239","BK1141","BK1576"],"gpt_icon":0},{"id":"2481997943","title":"中国癌症基金会与亚虹医药签署宫颈癌防控战略合作框架","url":"https://stock-news.laohu8.com/highlight/detail?id=2481997943","media":"中国网财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481997943?lang=zh_cn&edition=full","pubTime":"2024-11-07 10:03","pubTimestamp":1730944980,"startTime":"0","endTime":"0","summary":"为响应上述号召，中国癌症基金会与亚虹医药达成共同合作，进一步推进宫颈癌防控工作。此次合作旨在充分发挥中国癌症基金会与亚虹医药的优势，共同促进宫颈癌防控全链条体系建设，双方将借助协作组平台调研宫颈癌早诊早治现状，总结经验并提出优化措施。中国癌症基金会理事长张勇表示，宫颈癌是危害女性健康的重要疾病，其防控工作任重而道远。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241107101049a21e84b9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241107101049a21e84b9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2481894802","title":"亚虹医药：前三季度收入高于预期 APL-1706获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2481894802","media":"中金公司","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481894802?lang=zh_cn&edition=full","pubTime":"2024-11-07 00:00","pubTimestamp":1730908800,"startTime":"0","endTime":"0","summary":"APL-1702 提交上市申请，国际多中心III 期临床达主要终点。我们认为未来APL-1702 获批上市有望为宫颈癌前病变和HPV 病毒清除带来新治疗手段。2024 年11 月5 日，公司公告APL-1706获国家药监局批准上市，用于膀胱癌患者的膀胱镜检查。我们预计由于APL-1706 属于进口药品，获批后可能经历一段时间的生产准备环节再正式开始国内商业化。盈利预测与估值考虑到公司前三季度商业化收入超预期，我们上调2024 年收入预测26.9%至1.65 亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202411071341199f5930c3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202411071341199f5930c3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2481699935","title":"亚虹医药-U创1个月新高 2家券商给予增持建议","url":"https://stock-news.laohu8.com/highlight/detail?id=2481699935","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481699935?lang=zh_cn&edition=full","pubTime":"2024-11-06 09:30","pubTimestamp":1730856603,"startTime":"0","endTime":"0","summary":"11月06日，亚虹医药-U股价大幅上涨，截至09点30分，亚虹医药-U上涨5.31%，报7.53元/股，创近1个月新高，成交245万元，换手率0.09%，振幅0.56%。此外，数据统计显示，近半年内2家券商给予增持建议。主营业务及业绩亚虹医药-U公司主营业务为创新药物的研发、生产和销售。最新财报显示，今年三季报，亚虹医药-U实现营业收入1.39亿元，同比增长4537.79%，净利润为-2.71亿元，同比减少1.04%，基本每股收益为-0.48元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241106093336aba36ec0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241106093336aba36ec0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2481579055","title":"亚虹医药：华鑫医药投资者于11月5日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2481579055","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481579055?lang=zh_cn&edition=full","pubTime":"2024-11-05 19:11","pubTimestamp":1730805095,"startTime":"0","endTime":"0","summary":"证券之星消息，2024年11月5日亚虹医药发布公告称华鑫医药于2024年11月5日调研我司。亚虹医药2024年三季报显示，公司主营收入1.39亿元，同比上升4537.79%；归母净利润-2.71亿元，同比下降1.04%；扣非净利润-2.86亿元，同比上升2.65%；其中2024年第三季度，公司单季度主营收入5845.82万元，同比上升1903.16%；单季度归母净利润-8685.02万元，同比下降5.13%；单季度扣非净利润-8907.22万元，同比下降2.36%；负债率10.12%，投资收益1019.75万元，财务费用-1563.99万元，毛利率79.44%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110500031931.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1161","BK1515","BK1574","688176","159938","09939"],"gpt_icon":0},{"id":"2481752120","title":"亚虹医药(688176.SH)：APL-1706获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2481752120","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481752120?lang=zh_cn&edition=full","pubTime":"2024-11-05 17:13","pubTimestamp":1730798034,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚虹医药(688176.SH)公告，公司收到国家药品监督管理局核准签发的《药品注册证书》，批准公司APL-1706(灌注用盐酸氨酮戊酸己酯)上市。该药品用于膀胱癌(包括原位癌)患者的膀胱镜检查，包括既往的膀胱镜检查结果为疑似或已确诊的膀胱癌，或者随访期需要膀胱镜检查的患者。本品联合蓝光膀胱镜作为白光膀胱镜的辅助检查。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1206907.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688176"],"gpt_icon":0},{"id":"2480737126","title":"亚虹医药：累计回购约835万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2480737126","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480737126?lang=zh_cn&edition=full","pubTime":"2024-11-04 17:16","pubTimestamp":1730711783,"startTime":"0","endTime":"0","summary":"每经AI快讯，亚虹医药 11月4日晚间发布公告称，截至2024年10月31日，公司已累计回购股份约835万股，占公司总股本的比例为1.4651%，回购成交的最高价为人民币6.73元/股，最低价为人民币4.99元/股，支付的资金总额为人民币4778.7万元。2023年1至12月份，亚虹医药的营业收入构成为：医药制造业占比100.0%。截至发稿，亚虹医药市值为40亿元。道达号“个股趋势”提醒：1. 近30日内共有2批机构对亚虹医药-U调研，合计调研的机构家数为31家。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241104171718a2147e13&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241104171718a2147e13&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688176"],"gpt_icon":0},{"id":"2479088529","title":"亚虹医药：华源医药投资者于10月30日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2479088529","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479088529?lang=zh_cn&edition=full","pubTime":"2024-10-31 19:51","pubTimestamp":1730375486,"startTime":"0","endTime":"0","summary":"证券之星消息，2024年10月31日亚虹医药发布公告称华源医药于2024年10月30日调研我司。亚虹医药2024年三季报显示，公司主营收入1.39亿元，同比上升4537.79%；归母净利润-2.71亿元，同比下降1.04%；扣非净利润-2.86亿元，同比上升2.65%；其中2024年第三季度，公司单季度主营收入5845.82万元，同比上升1903.16%；单季度归母净利润-8685.02万元，同比下降5.13%；单季度扣非净利润-8907.22万元，同比下降2.36%；负债率10.12%，投资收益1019.75万元，财务费用-1563.99万元，毛利率79.44%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103100040496.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","BK1515","BK0239","BK1574","159938","BK1161","688176"],"gpt_icon":0},{"id":"2479324542","title":"图解亚虹医药三季报：第三季度单季净利润同比减5.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479324542","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479324542?lang=zh_cn&edition=full","pubTime":"2024-10-30 01:37","pubTimestamp":1730223434,"startTime":"0","endTime":"0","summary":"证券之星消息，亚虹医药2024年三季报显示，公司主营收入1.39亿元，同比上升4537.79%；归母净利润-2.71亿元，同比下降1.04%；扣非净利润-2.86亿元，同比上升2.65%；其中2024年第三季度，公司单季度主营收入5845.82万元，同比上升1903.16%；单季度归母净利润-8685.02万元，同比下降5.13%；单季度扣非净利润-8907.22万元，同比下降2.36%；负债率10.12%，投资收益1019.75万元，财务费用-1563.99万元，毛利率79.44%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103000001119.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176"],"gpt_icon":0},{"id":"2479923288","title":"亚虹医药：业绩说明会定于11月19日举行","url":"https://stock-news.laohu8.com/highlight/detail?id=2479923288","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479923288?lang=zh_cn&edition=full","pubTime":"2024-10-29 21:23","pubTimestamp":1730208215,"startTime":"0","endTime":"0","summary":"每经AI快讯，亚虹医药 10月29日晚间发布公告称，公司2024年第三季度业绩说明会定于2024年11月19日（星期二）上午10:00-11:30，以上证路演中心视频直播和网络互动的形式进行。出席本次业绩说明会的人员有：公司参加本次业绩说明会的人员包括董事长、总经理PANKE，董事会秘书兼财务负责人杨明远，独立董事黄彬。截至发稿，亚虹医药市值为40亿元。道达号“个股趋势”提醒：1. 近30日内共有1批机构对亚虹医药-U调研，合计调研的机构家数为30家。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241029212455ab7f0f0a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241029212455ab7f0f0a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688176"],"gpt_icon":0},{"id":"2479477633","title":"亚虹医药今年前三季度累计营收1.39亿元 两款商业化产品持续放量","url":"https://stock-news.laohu8.com/highlight/detail?id=2479477633","media":"和讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479477633?lang=zh_cn&edition=full","pubTime":"2024-10-29 18:56","pubTimestamp":1730199393,"startTime":"0","endTime":"0","summary":"10月29日晚，亚虹医药披露三季报，三季度公司实现营业收入5845.82万元，同比增长1903.16%；前三季度，累计营业收入为1.39亿元，同比增长4537.79%。营收增长主要系公司在2023年第四季度开始销售培唑帕尼片和马来酸奈拉替尼片，本报告期内商业化推广稳步推进，销量增加。和讯网站对文中陈述、观点判断保持中立，不对所包含内容的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241029185744ab7e98b6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241029185744ab7e98b6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688176"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2022-01-07","address":"江苏省泰州市海陵区药城大道一号(创业路东侧、园南路北侧)的新药创制基地二期D幢大楼1009房间","stockEarnings":[{"period":"1week","weight":-0.0181},{"period":"1month","weight":-0.0754},{"period":"3month","weight":0.4873},{"period":"6month","weight":0.3919},{"period":"1year","weight":-0.351},{"period":"ytd","weight":-0.295}],"companyName":"江苏亚虹医药科技股份有限公司","boardCode":"AI0027","perCapita":"13350股","boardName":"医药制造业","registeredCapital":"57000万元","compareEarnings":[{"period":"1week","weight":-0.0036},{"period":"1month","weight":-0.0138},{"period":"3month","weight":0.2544},{"period":"6month","weight":0.1185},{"period":"1year","weight":0.1463},{"period":"ytd","weight":0.1402}],"survey":"　　江苏亚虹医药科技股份有限公司的主营业务是泌尿生殖系统（UrogenitalSystem）肿瘤及其它重大疾病领域创新药的研发、生产和销售。公司的主要产品是APL-1702、APL-1202、APL-1501(第二代APL-1202)、APL-1706、APLD-2304、AT-014、AT-020、APL-2302、AT-017、AT-018、AT-021、APL-1401、APL-2301。","serverTime":1734107421717,"listedPrice":22.98,"stockholders":"27825人(较上一季度减少2.80%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"亚虹医药(688176)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供亚虹医药(688176)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"亚虹医药,688176,亚虹医药股票,亚虹医药股票老虎,亚虹医药股票老虎国际,亚虹医药行情,亚虹医药股票行情,亚虹医药股价,亚虹医药股市,亚虹医药股票价格,亚虹医药股票交易,亚虹医药股票购买,亚虹医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"亚虹医药(688176)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供亚虹医药(688176)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}